Role of histone modifications in regulating immune cell function in diffuse large B-cell lymphoma

doi:10.16352/j.issn.1001-6325.2026.05.0711

Abstract

Abstract: Diffuse large B-cell lymphoma (DLBCL) exhibits complex pathogenesis and significant heterogeneity. In DLBCL, histone modifications serve as a core mechanism of epigenetic regulation, dependent on the dynamic regulation of key modifying enzymes. Mutations or inactivation of key modifying enzymes such as KMT2D, EZH2, CREBBP, and EP300 lead to abnormal modifications at H3K4, H3K18, and H3K27 sites. These alterations mediate abnormal activation or suppression of downstream genes, ultimately affecting the expression of proteins like MYC, TP53 and BCL6 to promote cell proliferation and malignant transformation. Concurrently, histone modifications promote tumor-associated macrophages(TAMs) polarization by mediating signaling pathways like FBXW7/NOTCH/MYC/TGF-β1 and FBXW7/NOTCH/CCL2/CSF1. This suppresses T-cell activation and killing functions, disrupts anti-tumor immune homeostasis, and facilitates immune escape in DLBCL cells.

Key words: diffuse large B-cell lymphoma(DLBCL), histone modifications, immune cell

CLC Number:

R733.4

JIAO Lichao, ZHU Yubing, WANG Cancan, FENG Ning, LI Xinxia. Role of histone modifications in regulating immune cell function in diffuse large B-cell lymphoma[J]. Basic & Clinical Medicine, 2026, 46(5): 711-716.

References 25

[1]	李瑗春,严学倩,范丹,等. AP2M1抑制弥漫性大B细胞淋巴瘤细胞增殖和侵袭[J]. 基础医学与临床, 2024, 44: 308-316.
[2]	Shen R, Fu D, Dong L, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma[J]. Signal Transduct Target Ther, 2023, 8:145.doi: 10.1038/s41392-023-01358-y.
[3]	He M, Liu M, Yuan J, et al. Spatial transcriptomics reveals tumor microenvironment heterogeneity in EBV positive diffuse large B cell lymphoma[J]. Sci Rep, 2025, 15: 15878. doi: 10.1038/s41598-025-00410-x.
[4]	Guan X, Wang Y, Fang T, et al. Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large B-cell lymphomas and regulates the pro-tumor microenvironment[J]. Haematologica, 2025, 110: 425-438.
[5]	Lian J, Zhang X, Chen W, et al. Revealing putative causal genes by establishing the causality between different lymphomas and immune cells[J]. J Cell Mol Med, 2025, 29: e70535.doi: 10.1111/jcmm.70535.
[6]	Tian T, Li J, Shi D, et al. SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription[J]. Cell Death Dis, 2022, 13: 763. doi: 10.1038/s41419-022-05208-7.
[7]	Sudholz H, Schuster IS, Foroutan M, et al. DOT1L maintains NK cell phenotype and function for optimal tumor control[J]. Cell Rep, 2024, 43:114333.doi: 10.1016/j.celrep.2024.114333.
[8]	Kealy LC, Russ BE, Turner SJ, et al. DOT1L-mediated H3K79me2 directs B-cell repertoire establishment, marginal zone development, and germinal center function[J]. J Immunol, 2026,215.doi: 10.1093/jimmun/vkaf243.
[9]	Duan S, Lou X, Chen S, et al. Macrophage LMO7 deficiency facilitates inflammatory injury via metabolic-epigenetic reprogramming[J]. Acta Pharm Sin B, 2023, 13: 4785-4800.
[10]	Liu M, Bertolazzi G, Sridhar S, et al. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma[J]. Nat Commun, 2024, 15:2113.doi: 10.1038/s41467-024-46220-z.
[11]	Picavet LW, Samat AAK, Calis J, et al. CREBBP/EP300 inhibition impairs CD4+ T cell activation: implications for autoimmu disorders[J]. Biomedicines, 2024, 12: 1344.doi: 10.3390/biomedicines12061344.
[12]	Ma S, Ming Y, Wu J, et al. Cellular metabolism regulates the differentiation and function of T-cell subsets[J]. Cell Mol Immunol, 2024, 21: 419-435.
[13]	Zhu Q, Yang Y, Chen K, et al. Diffuse large B-cell lymphoma: the significance of CD8+ tumor-infiltrating lymphocytes exhaustion mediated by TIM3/Galectin-9 pathway[J]. J Transl Med, 2024, 22:174.doi: 10.1186/s12967-024-05002-3.
[14]	Huang YH, Cai K, Xu PP, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis[J]. Signal Transduct Target Ther, 2021, 6: 10.doi: 10.1038/s41392-020-00437-8.
[15]	Sun Y, Xu Z, Wang Z, et al. KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis[J]. J Leukoc Biol, 2025,117. doi: 10.1093/jleuko/qiaf092.
[16]	Chu L, Tan D, Zhu M, et al. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance[J]. J Biol Chem, 2023, 299:103073.doi: 10.1016/j.jbc.2023.103073.
[17]	Walker JS, Wenzl K, Novak JP, et al. Integrated genomics with refined cell-of-origin subtyping distingui-shes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma[J]. Blood Cancer J, 2025, 15:120.doi: 10.1038/s41408-025-01326-5.
[18]	Zhang J, Vlasevska S, Wells VA, et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma[J]. Cancer Discov, 2017, 7: 322-337.doi: 10.1158/2159-8290.CD-16-1417.
[19]	Kimpara S, Lu L, Hoang NM, et al. EGR1 addiction in diffuse large B-cell lymphoma[J]. Mol Cancer Res, 2021,19:1258-1269.
[20]	Liu QX, Zhu Y, Yi HM, et al. KMT2D mutations promoted tumor progression in diffuse large B-cell lympho-ma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis[J]. Int J Biol Sci, 2024, 20: 3972-3985.doi: 10.7150/ijbs.93349.
[21]	An R, Zhang Z, Zhang D, et al. A novel EZH1/2 dual inhibitor inhibits GCB DLBCL through cell cycle regula-tion and M2 tumor-associated macrophage polarization[J]. J Biol Chem, 2024, 300:107788. doi: 10.1016/j.jbc.2024.107788.
[22]	Autio M, Brück O, Pollari M, et al. Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas[J]. Haematologica, 2024, 110: 1339-1350.
[23]	Kim S, Jeong H, Ahn HK, et al. Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL[J]. Blood Adv, 2024, 8: 5773-5788.doi: 10.1182/bloodadvances.2024013699.
[24]	Zhang D, Tang Z, Huang H, et al. Metabolic regulation of gene expression by histone lactylation[J]. Nature, 2019, 574: 575-580.
[25]	Britto LS, Balasubramani D, Desai S, et al. T cells spatially regulate B cell receptor signaling in lymphomas through H3K9me3 modifications[J]. Adv Healthc Mater, 2025, 14: 2401192.doi:10.1002/adhm.202401192.